Indication

T-cell acute lymphoblastic leukemia

T-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled proliferation and accumulation of immature T-cell lymphoblasts in the bone marrow and peripheral blood. Read more about T-cell acute lymphoblastic leukemia

13 drugs 13 manufacturers

Advertisement

Drugs that treat it

Common T-cell acute lymphoblastic leukemia therapies.

Showing 10–13 of 13 drugs

NELARABINE

PURINE ANALOGUES·T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA·+1
X-GEN PHARMACEU

NELARABINE

PURINE ANALOGUES·T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA·+1
ZYDUS USA-NOVAP

NELARABINE

PURINE ANALOGUES·T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA·+1
Amneal Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with T-cell acute lymphoblastic leukemia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About T-cell acute lymphoblastic leukemia.

T-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled proliferation and accumulation of immature T-cell lymphoblasts in the bone marrow and peripheral blood.

It affects the lymphoid and hematopoietic systems across both pediatric and adult populations, accounting for approximately 10% to 15% of childhood and up to 25% of adult acute lymphoblastic leukemia cases.

Pathophysiologically, the disease arises from multistep oncogenic mutations—such as activating alterations in *NOTCH1*—that cause differentiation arrest during thymocyte development.

Clinically, it frequently presents with marked leukocytosis, bone marrow failure causing cytopenias, an anterior mediastinal mass from thymic expansion, and a predilection for central nervous system infiltration.

Personalize your experience

Follow T-cell acute lymphoblastic leukemia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it